Candidates: Treatments, vaccines, and nanotechnology-based diagnostics

Category: VAX

Types: To be determined

Status: The Tulane National Primate Research Center (TNPRC) said March 25 it was working on COVID-19 drugs, vaccines, and nanotechnology-based diagnostics, after becoming one of the first research facilities in the country to obtain approval from the U.S. Centers for Disease Control and Prevention (CDC) to receive live samples of COVID-19. TNPRC researchers are creating a nonhuman primate model to study COVID-19’s clinical progression, how it is transmitted through the air and how it specifically affects aging populations.

TNPRC Director Jay Rappaport, PhD, will lead researchers—who include Tony Hu, PhD, Weatherhead Presidential Chair in Biotechnology Innovation is working to develop a rapid test for COVID-19 using highly sensitive blood or saliva tests. Tulane announced the launch of its COVID-19 research program in February.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

Previous articleImpact BioMedical – Linebacker and Equivir
Next articleHeat Biologics and University of Miami – gp96-Ig-S